Review Article
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
Table 1
Characteristics of included studies and quality assessing of non-randomized studies with Newcastle-Ottawa Scale (NOS).
| | Reference | Year | Country | Inclusion criteria | Follow-up | Adjusting factors | NOS |
| | Berruti [16] | 2017 | Italy | 1985-2003
≥ 18 years old
R0, R1
Stage I-IV
No radiotherapy | >128/>200
months | Age
Gender
Stage | 8 | | Postlewait [27] | 2016 | USA | 1993-2014
R0, R1,R2
Stage I-IV
Allowed radiotherapy | 44/>60
months | Age
Function
Stage
Surgical margins
Radiotherapy et al. | 7 | | Berruti [28] | 2014 | Italy
Germany
Holland
France
USA | 1990-2008
≥ 18 years old
R0
Stage I-IV
Allowed radiotherapy | 50/>120
months | Age
Gender
Function
Stage | 7 | | Grubbs [29] | 2010 | USA | 1991-2008
R0, R1, Rx
Stage I-IV | 88/>100
Months | Age
Gender
Function
Stage
Institution | 8 | | Fassnacht [30] | 2010 | Germany | 1990-2009
R0, R1, R2, Rx
Stage II
Allowed radiotherapy | 38/>60
months | Surgical margins
Mitotic count | 7 |
|
|
a R0 denotes microscopically negative margin; R1 denotes microscopically positive margin; R2 denotes grossly positive margin.
b Median/maximum length of follow-up.
c Prognostic factors adjusted for mitotane in multivariate Cox regression model.
|
